Gene expression profiling of the tumor microenvironment has proven effective in measuring immune response during research in cancer progression and therapeutic response. Preconfigured quantitative PCR (qPCR) panels containing hundreds of gene targets represent a potential solution, but can require significant time and resources to implement in the laboratory and can be difficult to customize for specific experimental needs.
The Advanta™ IO Gene Expression Assay workflow was designed to meet this need, detecting 170 gene expression markers involved in checkpoint therapeutic response. Ideal for accelerating the identification of potential predictive biomarker signatures of checkpoint immunotherapeutic response, the Advanta IO Gene Expression Assay was developed in collaboration with leading researchers from academia and biopharma to provide the right balance of biomarker breadth, assay flexibility and workflow efficiency.
As an expanded workflow solution, we now offer an optimized Advanta FFPE RNA Extraction Kit, which produces high-quality RNA from precious tumor samples and improves the sensitivity of tumor transcript detection. As an added benefit, a synthetic template representing the amplification targets of all 170 genes is also available as a positive control. When using this new kit and control together with the Advanta IO Gene Expression Assay on the Biomark™ HD system, researchers can accurately assess 24 to 96 tumor samples at a time with high confidence and efficiency.
Completing the workflow, the GO Immuno-Oncology Workbench was developed by GenomOncology to provide powerful, flexible and intuitive analysis of immuno-oncology datasets. Now available from Fluidigm, the GO Immuno-Oncology Workbench enables researchers to unlock new clinical insights from translational immuno-oncology studies, including the identification of meaningful gene expression biomarkers that correlate with therapeutic response.
“The GO Immuno-Oncology Workbench is a powerful software tool that enables comprehensive analysis of immuno-oncology cohorts, integrating molecular and phenotypic data together with immuno-oncology-specific annotations to power translational studies,” said Manuel Glynias, CEO of GenomOncology. “We are excited to see the new insights uncovered using this comprehensive approach, which we we offer in conjunction with Fluidigm to empower the growing immuno-oncology community.”
“Fluidigm is the partner of choice within the immuno-oncology research community, enabling deep interrogation of the tumor microenvironment and immune response with mass cytometry,” said Chris Linthwaite, President and CEO of Fluidigm. “In partnership with GenomOncology, we are expanding our immuno-oncology gene expression offering to the cancer community with a full microfluidics-based workflow solution from RNA extraction to data analysis. By providing a comprehensive view of tumor immunity, utilizing microfluidics and mass cytometry technologies, we are empowering researchers to uncover unique health insights that could transform the future of cancer care.”